公开(公告)号：WO2008067164A2

公开(公告)日：2008-06-05

申请号：PCT/US2007/084617

申请日：2007-11-14

Applicant: ABBOTT LABORATORIES ,  BERNDL, Gunther ,  ROSENBERG, Joerg ,  FASTNACHT, Katja ,  LIEPOLD, Bernd ,  BREITENBACH, Joerg ,  JUNG, Tina ,  ROTH, Wolfgang ,  MORRIS, John ,  KLEIN, Cheri, E. ,  CAI, Yan ,  ALANI, Laman ,  GHOSH, Soumojeet

Inventor： BERNDL, Gunther ,  ROSENBERG, Joerg ,  FASTNACHT, Katja ,  LIEPOLD, Bernd ,  BREITENBACH, Joerg ,  JUNG, Tina ,  ROTH, Wolfgang ,  MORRIS, John ,  KLEIN, Cheri, E. ,  CAI, Yan ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K9/20 ,  A61K31/427

CPC classification number: A61K31/427 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2095

Abstract: The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.

Abstract translation: 本发明的特征在于包含利托那韦的固体药物剂型。 作为非限制性实例，本发明的剂型包含利托那韦在基质中的固体分散体或固体溶液，其中基质包含至少一种水溶性聚合物如共聚维酮，和至少一种表面活性剂，例如 作为聚氧乙烯40氢化蓖麻油或聚乙二醇羟基硬脂酸酯。 优选地，固体分散体或溶液不包括或仅包含不显着量的PEG。

公开(公告)号：EP2112925A2

公开(公告)日：2009-11-04

申请号：EP07871461.5

申请日：2007-11-14

Applicant: Abbott Laboratories

Inventor： BERNDL, Gunther ,  ROSENBERG, Joerg ,  FASTNACHT, Katja ,  LIEPOLD, Bernd ,  BREITENBACH, Joerg ,  JUNG, Tina ,  ROTH, Wolfgang ,  MORRIS, John ,  KLEIN, Cheri E. ,  CAI, Yan ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K9/28 ,  A01N43/54 ,  A01N43/78

CPC classification number: A61K31/427 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2095

Abstract: The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.